Short Interest: How Analysts Feel About Akorn Incorporated (NASDAQ:AKRX) After Increase in Sellers?

November 23, 2016 - By Clifton Ray   ·   0 Comments

Short Interest: How Analysts Feel About Akorn Incorporated (NASDAQ:AKRX) After Increase in Sellers?

The stock of Akorn Incorporated (NASDAQ:AKRX) registered an increase of 24.21% in short interest. AKRX’s total short interest was 12.19 million shares in November as published by FINRA. Its up 24.21% from 9.82M shares, reported previously. With 1.09M shares average volume, it will take short sellers 11 days to cover their AKRX’s short positions. The short interest to Akorn Incorporated’s float is 14.87%. About 1.00M shares traded hands. Akorn, Inc. (NASDAQ:AKRX) has declined 23.48% since April 21, 2016 and is downtrending. It has underperformed by 28.81% the S&P500.

Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical firm that develops, makes and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. The company has a market cap of $2.77 billion. The Firm operates through two divisions: Prescription Pharmaceuticals and the Consumer Health. It has a 15.1 P/E ratio. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays.

Akorn, Inc. (NASDAQ:AKRX) Ratings Coverage

Out of 14 analysts covering Akorn Inc (NASDAQ:AKRX), 6 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 43% are positive. Akorn Inc has been the topic of 21 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Jefferies maintained Akorn, Inc. (NASDAQ:AKRX) on Wednesday, March 23 with “Buy” rating. The firm has “Underperform” rating given on Monday, November 7 by Bank of America. The firm has “Overweight” rating by JP Morgan given on Monday, March 14. The stock has “Hold” rating given by Deutsche Bank on Friday, August 5. The company was maintained on Wednesday, March 23 by Susquehanna. On Friday, February 12 the stock rating was maintained by RBC Capital Markets with “Outperform”. The rating was initiated by JMP Securities with “Market Perform” on Wednesday, September 9. The rating was upgraded by Nomura to “Buy” on Wednesday, December 2. The firm has “Buy” rating given on Friday, August 5 by WallachBeth Capital. The company was maintained on Wednesday, March 16 by Leerink Swann.

AKRX Company Profile

Akorn Inc. (Akorn), incorporated on January 20, 1971, together with its subsidiaries, is a specialty pharmaceutical firm that develops, makes and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Firm operates through two divisions: Prescription Pharmaceuticals and the Consumer Health. The Firm is engaged in the development, manufacturing and marketing of generic pharmaceutical products in alternative dosage forms. It is focused on sterile and non-sterile dosage forms including, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. The Company’s OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products, including dry eye therapy lubricating eye drops, eyelid and eyelash cleansing foam and eye nutrition supplements.

More recent Akorn, Inc. (NASDAQ:AKRX) news were published by: Fool.com which released: “The Ridiculous Reason Akorn, Inc. Shares Dropped as Much as 17.4% Today” on November 03, 2016. Also Forbes.com published the news titled: “Oversold Conditions For Akorn (AKRX)” on November 03, 2016. Finance.Yahoo.com‘s news article titled: “Robbins Arroyo LLP: Akorn, Inc. (AKRX) Misled Shareholders According to a …” with publication date: October 28, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>